Connecting Academic Discovery, Platform R&D & Global Commercialisation
Breakthrough genetic medicine development requires cross-functional collaboration between academic labs, research funding bodies, dedicated technology innovators and global commercialisation partners. Branca Bunús leads a complete interconnected ecosystem built entirely around our proprietary HPAE delivery platform.
Ecosystem core structure
The entire HPAE innovation value chain originates from UCD academic research, is advanced exclusively by Branca Bunús for therapeutic pipeline and polymer platform innovation, with all reagent product global market activity delegated to strategic partner PolyGene Biotech under exclusive commercial licensing terms. The ecosystem is supported by Irish national innovation funding bodies Enterprise Ireland and Research Ireland.
UCD academic research
BrB platform & therapeutics
PolyGene global commercialisation
Irish national innovation support
One Shared HPAE Vision, Two Complementary Strategic Focuses
A single platform, advanced from Dublin and delivered to research, biomanufacturing and clinical partners worldwide.
Branca Bunús Ltd
- HPAE platform IP ownership and core polymer R&D
- Pre-clinical in-vivo gene medicine pipeline development (BRB101 / BRB202)
- Academic and therapeutic licensing collaboration
PolyGene Biotech
- Exclusive global transfection reagent manufacturing and distribution
- BrPERfect / TransPi product technical customer support
- Reagent formulation iterative optimisation for biomanufacturing workflows
Independent legal entities, shared founding core team, aligned long-term HPAE platform growth goals.
Strategic partnership
Branca Bunús Ltd and PolyGene Biotech operate as independent entities under a long-term strategic partnership, founded by the HPAE technology inventor Professor Wenxin Wang. BrB retains the ownership of HPAE platform intellectual property and leads therapeutic pipeline development; PolyGene holds exclusive global manufacturing, distribution and commercialisation rights for all transfection reagent lines.
Academic research partner: University College Dublin
Long-standing continuous collaboration with Professor Wenxin Wang’s UCD Charles Institute lab, including joint I-Form Centre polymer research programmes and industry PhD training initiatives funded by Research Ireland to advance next-generation HPAE polymer variants.
Irish national innovation support
As an Enterprise Ireland High Potential Start-Up, Branca Bunús receives structured government innovation support for international expansion, R&D project funding and market validation via Research Ireland and Enterprise Ireland collaborative research grants.
Ecosystem expansion roadmap
We continuously expand our global partner network including academic institutions, biotech startups, large pharma groups, clinical trial organisations and global reagent distribution partners to unlock the full HPAE platform potential.